Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles by Patrick T. O'Gara
Based on 15 articles published since 2008
||||

Between 2008 and 2019, Patrick T. O'Gara wrote the following 15 articles about Coronary Artery Disease.
 
+ Citations + Abstracts
1 Guideline 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2016

Levine, Glenn N / Bates, Eric R / Bittl, John A / Brindis, Ralph G / Fihn, Stephan D / Fleisher, Lee A / Granger, Christopher B / Lange, Richard A / Mack, Michael J / Mauri, Laura / Mehran, Roxana / Mukherjee, Debabrata / Newby, L Kristin / O'Gara, Patrick T / Sabatine, Marc S / Smith, Peter K / Smith, Sidney C / Halperin, Jonathan L / Levine, Glenn N / Al-Khatib, Sana M / Birtcher, Kim K / Bozkurt, Biykem / Brindis, Ralph G / Cigarroa, Joaquin E / Curtis, Lesley H / Fleisher, Lee A / Gentile, Federico / Gidding, Samuel / Hlatky, Mark A / Ikonomidis, John S / Joglar, José A / Pressler, Susan J / Wijeysundera, Duminda N. · ·J Thorac Cardiovasc Surg · Pubmed #27751237.

ABSTRACT: -- No abstract --

2 Guideline 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2016

Levine, Glenn N / Bates, Eric R / Bittl, John A / Brindis, Ralph G / Fihn, Stephan D / Fleisher, Lee A / Granger, Christopher B / Lange, Richard A / Mack, Michael J / Mauri, Laura / Mehran, Roxana / Mukherjee, Debabrata / Newby, L Kristin / O'Gara, Patrick T / Sabatine, Marc S / Smith, Peter K / Smith, Sidney C. · ·J Am Coll Cardiol · Pubmed #27036918.

ABSTRACT: -- No abstract --

3 Guideline Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. 2015

Rosendorff, Clive / Lackland, Daniel T / Allison, Matthew / Aronow, Wilbert S / Black, Henry R / Blumenthal, Roger S / Cannon, Christopher P / de Lemos, James A / Elliott, William J / Findeiss, Laura / Gersh, Bernard J / Gore, Joel M / Levy, Daniel / Long, Janet B / O'Connor, Christopher M / O'Gara, Patrick T / Ogedegbe, Gbenga / Oparil, Suzanne / White, William B / Anonymous4500825. · ·Circulation · Pubmed #25829340.

ABSTRACT: -- No abstract --

4 Guideline 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. 2008

Bonow, Robert O / Carabello, Blase A / Chatterjee, Kanu / de Leon, Antonio C / Faxon, David P / Freed, Michael D / Gaasch, William H / Lytle, Bruce W / Nishimura, Rick A / O'Gara, Patrick T / O'Rourke, Robert A / Otto, Catherine M / Shah, Pravin M / Shanewise, Jack S / Anonymous3120610. · ·J Am Coll Cardiol · Pubmed #18848134.

ABSTRACT: -- No abstract --

5 Editorial Multivessel CAD in Nondiabetic Patients: To Operate or to Dilate? 2016

Jaffer, Farouc A / O'Gara, Patrick T. ·Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: fjaffer@mgh.harvard.edu. · Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address: pogara@partners.org. ·J Am Coll Cardiol · Pubmed #27364048.

ABSTRACT: -- No abstract --

6 Editorial The prognostic value of cardiac CT after coronary artery bypass surgery as easy as 1, 2, 3? 2011

O'Gara, Patrick T / Blankstein, Ron. · ·JACC Cardiovasc Imaging · Pubmed #21565738.

ABSTRACT: -- No abstract --

7 Editorial The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial: can we deliver on its promise? 2010

O'Gara, Patrick T. ·Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. pogara@partners.org ·J Am Coll Cardiol · Pubmed #20338497.

ABSTRACT: -- No abstract --

8 Editorial One more step for computed tomography coronary angiography before heart valve surgery. 2009

O'Gara, Patrick T. · ·Circ Cardiovasc Imaging · Pubmed #19808607.

ABSTRACT: -- No abstract --

9 Review PCI Strategies in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Artery Disease. 2016

Bates, Eric R / Tamis-Holland, Jacqueline E / Bittl, John A / O'Gara, Patrick T / Levine, Glenn N. ·Division of Cardiovascular Diseases, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan. Electronic address: ebates@umich.edu. · Division of Cardiology, Department of Internal Medicine, Mount Sinai St. Luke's Hospital, New York, New York. · Munroe Heart and Vascular Institute, Munroe Regional Medical Center, Ocala, Florida. · Cardiovascular Division, Department of Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts. · Section of Cardiology, Michael E. DeBakey Medical Center, Baylor College of Medicine, Houston, Texas. ·J Am Coll Cardiol · Pubmed #27585512.

ABSTRACT: Recent randomized controlled trials have suggested that patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease may benefit more from multivessel percutaneous coronary intervention (PCI) compared with culprit vessel-only primary PCI. The American College of Cardiology, American Heart Association, and Society for Cardiovascular Angiography and Interventions recently published an updated recommendation on this topic. The purpose of this State-of-the-Art Review is to accurately document existing published reports, describe their limitations, and establish a base for future studies.

10 Review 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. 2016

Levine, Glenn N / Bates, Eric R / Bittl, John A / Brindis, Ralph G / Fihn, Stephan D / Fleisher, Lee A / Granger, Christopher B / Lange, Richard A / Mack, Michael J / Mauri, Laura / Mehran, Roxana / Mukherjee, Debabrata / Newby, L Kristin / O'Gara, Patrick T / Sabatine, Marc S / Smith, Peter K / Smith, Sidney C. ·Focused Update writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix 1 for detailed information. ACC/AHA Task Force on Clinical Practice Guidelines Liaison. ACC/AHA Representative. Evidence Review Committee Chair. American Society of Anesthesiologists/Society of Cardiovascular Anesthesiologists Representative. American Association for Thoracic Surgery/Society of Thoracic Surgeons Representative. Society for Cardiovascular Angiography and Interventions Representative. ·Circulation · Pubmed #27026020.

ABSTRACT: -- No abstract --

11 Review Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. 2015

Rosendorff, Clive / Lackland, Daniel T / Allison, Matthew / Aronow, Wilbert S / Black, Henry R / Blumenthal, Roger S / Cannon, Christopher P / de Lemos, James A / Elliott, William J / Findeiss, Laura / Gersh, Bernard J / Gore, Joel M / Levy, Daniel / Long, Janet B / O'Connor, Christopher M / O'Gara, Patrick T / Ogedegbe, Olugbenga / Oparil, Suzanne / White, William B / Anonymous7240825. · ·J Am Soc Hypertens · Pubmed #25840695.

ABSTRACT: -- No abstract --

12 Review Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. 2015

Rosendorff, Clive / Lackland, Daniel T / Allison, Matthew / Aronow, Wilbert S / Black, Henry R / Blumenthal, Roger S / Cannon, Christopher P / de Lemos, James A / Elliott, William J / Findeiss, Laura / Gersh, Bernard J / Gore, Joel M / Levy, Daniel / Long, Janet B / O'Connor, Christopher M / O'Gara, Patrick T / Ogedegbe, Gbenga / Oparil, Suzanne / White, William B / Anonymous4440825. · ·Hypertension · Pubmed #25828847.

ABSTRACT: -- No abstract --

13 Article Yield of downstream tests after exercise treadmill testing: a prospective cohort study. 2014

Christman, Mitalee P / Bittencourt, Marcio Sommer / Hulten, Edward / Saksena, Ekta / Hainer, Jon / Skali, Hicham / Kwong, Raymond Y / Forman, Daniel E / Dorbala, Sharmila / O'Gara, Patrick T / Di Carli, Marcelo F / Blankstein, Ron. ·Harvard Medical School, Boston, Massachusetts. · Department of Medicine (Cardiovascular Division) and Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. · Boston University, Boston, Massachusetts. · Department of Medicine (Cardiovascular Division), Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. · Department of Medicine (Cardiovascular Division) and Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: rblankstein@partners.org. ·J Am Coll Cardiol · Pubmed #24509269.

ABSTRACT: OBJECTIVES: The purpose of this study was to estimate the frequency and results of downstream testing after exercise treadmill tests (ETTs). BACKGROUND: The utility of additional diagnostic testing after ETT is not well characterized. METHODS: We followed consecutive individuals without known coronary artery disease referred for clinical ETT at a large medical center. We measured the frequency and results of downstream imaging tests and invasive angiography within 6 months of ETT and the combined endpoint of survival free from cardiovascular death, myocardial infarction, and coronary revascularization. RESULTS: Among 3,656 consecutive subjects who were followed for a mean of 2.5 ± 1.1 years, 332 (9.0%) underwent noninvasive imaging and 84 (2.3%) were referred directly to invasive angiography after ETT. The combined endpoint occurred in 76 (2.2%) patients. The annual incidence of the combined endpoint after negative, inconclusive, and positive ETT was 0.2%, 1.3%, and 12.4%, respectively (p < 0.001). Rapid recovery of electrocardiography (ECG) changes during ETT was associated with negative downstream test results and excellent prognosis, whereas typical angina despite negative ECG was associated with positive downstream tests and adverse prognosis (p < 0.001). Younger age, female sex, higher metabolic equivalents of task achieved, and rapid recovery of ECG changes were predictors of negative downstream tests. CONCLUSIONS: Among patients referred for additional testing after ETT, the lowest yield was observed among individuals with rapid recovery of ECG changes or negative ETT, whereas the highest yield was observed among those with typical angina despite negative ECG or a positive ETT. These findings may be used to identify patients who are most and least likely to benefit from additional testing.

14 Article Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. 2014

Acker, Michael A / Parides, Michael K / Perrault, Louis P / Moskowitz, Alan J / Gelijns, Annetine C / Voisine, Pierre / Smith, Peter K / Hung, Judy W / Blackstone, Eugene H / Puskas, John D / Argenziano, Michael / Gammie, James S / Mack, Michael / Ascheim, Deborah D / Bagiella, Emilia / Moquete, Ellen G / Ferguson, T Bruce / Horvath, Keith A / Geller, Nancy L / Miller, Marissa A / Woo, Y Joseph / D'Alessandro, David A / Ailawadi, Gorav / Dagenais, Francois / Gardner, Timothy J / O'Gara, Patrick T / Michler, Robert E / Kron, Irving L / Anonymous550776. ·From the Department of Surgery, Division of Cardiovascular Surgery, University of Pennsylvania School of Medicine, Philadelphia (M.A.A., Y.J.W.) · the International Center for Health Outcomes and Innovation Research (InCHOIR), Department of Health Evidence and Policy, Mount Sinai School of Medicine (M.K.P., A.J.M., A.C.G., D.D.A., E.B., E.G.M.), Division of Cardiothoracic Surgery, Department of Surgery, College of Physicians and Surgeons, Columbia University (M.A.), and the Department of Cardiothoracic Surgery, Montefiore Medical Center and Albert Einstein College of Medicine (D.A.D., R.E.M.) - all in New York · Montreal Heart Institute, University of Montreal, Montreal (L.P.P.) · Institut Universitaire de Cardiologie de Québec, Hôpital Laval, Quebec, QC, Canada (P.V., F.D.) · the Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham (P.K.S.), and the Department of Cardiovascular Sciences, East Carolina Heart Institute at East Carolina University, Greenville (T.B.F.) - both in North Carolina · Echocardiography Core Lab, Massachusetts General Hospital (J.W.H.), and Cardiovascular Division, Brigham and Women's Hospital (P.T.O.) - both in Boston · the Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland (E.H.B.) · Clinical Research Unit, Division of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta (J.D.P.) · Division of Cardiac Surgery, University of Maryland School of Medicine, Baltimore (J.S.G.) · Baylor Research Institute, Dallas (M.M.) · National Institutes of Health (NIH) Heart Center at Suburban Hospital (K.A.H.), and the Office of Biostatistics Research (N.L.G.) and the Division of Cardiovascular Sciences (M.A.M.), NIH - all in Bethesda, MD · the Division of Thoracic and Cardiovascular Surgery, University of Virginia School of Medicine, Charlottesville (G.A., I.L.K.) · and the Center for Heart and Vascular Health, Christiana Care Health System, Newark, DE (T.J ·N Engl J Med · Pubmed #24245543.

ABSTRACT: BACKGROUND: Ischemic mitral regurgitation is associated with a substantial risk of death. Practice guidelines recommend surgery for patients with a severe form of this condition but acknowledge that the supporting evidence for repair or replacement is limited. METHODS: We randomly assigned 251 patients with severe ischemic mitral regurgitation to undergo either mitral-valve repair or chordal-sparing replacement in order to evaluate efficacy and safety. The primary end point was the left ventricular end-systolic volume index (LVESVI) at 12 months, as assessed with the use of a Wilcoxon rank-sum test in which deaths were categorized below the lowest LVESVI rank. RESULTS: At 12 months, the mean LVESVI among surviving patients was 54.6±25.0 ml per square meter of body-surface area in the repair group and 60.7±31.5 ml per square meter in the replacement group (mean change from baseline, -6.6 and -6.8 ml per square meter, respectively). The rate of death was 14.3% in the repair group and 17.6% in the replacement group (hazard ratio with repair, 0.79; 95% confidence interval, 0.42 to 1.47; P=0.45 by the log-rank test). There was no significant between-group difference in LVESVI after adjustment for death (z score, 1.33; P=0.18). The rate of moderate or severe recurrence of mitral regurgitation at 12 months was higher in the repair group than in the replacement group (32.6% vs. 2.3%, P<0.001). There were no significant between-group differences in the rate of a composite of major adverse cardiac or cerebrovascular events, in functional status, or in quality of life at 12 months. CONCLUSIONS: We observed no significant difference in left ventricular reverse remodeling or survival at 12 months between patients who underwent mitral-valve repair and those who underwent mitral-valve replacement. Replacement provided a more durable correction of mitral regurgitation, but there was no significant between-group difference in clinical outcomes. (Funded by the National Institutes of Health and the Canadian Institutes of Health; ClinicalTrials.gov number, NCT00807040.).

15 Article Design, rationale, and initiation of the Surgical Interventions for Moderate Ischemic Mitral Regurgitation Trial: a report from the Cardiothoracic Surgical Trials Network. 2012

Smith, Peter K / Michler, Robert E / Woo, Y Joseph / Alexander, John H / Puskas, John D / Parides, Michael K / Hahn, Rebecca T / Williams, Judson B / Dent, John M / Ferguson, T Bruce / Moquete, Ellen / Rose, Eric A / Pagé, Pierre / Jeffries, Neal O / O'Gara, Patrick T / Ascheim, Deborah D. ·Division of Cardiovascular and Thoracic Surgery, Duke University, Durham, NC, USA. ·J Thorac Cardiovasc Surg · Pubmed #21788032.

ABSTRACT: OBJECTIVE: Patients with coronary artery disease complicated by moderate ischemic mitral regurgitation have demonstrably poorer outcome than do patients with coronary artery disease but without mitral regurgitation. The optimal treatment of this condition has become increasingly controversial, and a randomized trial evaluating current practices is warranted. METHODS: We describe the design and initial execution of the Cardiothoracic Surgical Trials Network Surgical Interventions for Moderate Ischemic Mitral Regurgitation Trial. RESULTS: This is an ongoing prospective, multicenter, randomized, controlled clinical trial designed to test the safety and efficacy of mitral repair in addition to coronary artery bypass grafting in the treatment of moderate ischemic mitral regurgitation. CONCLUSIONS: The results of the Cardiothoracic Surgical Trials Network Surgical Interventions for Moderate Ischemic Mitral Regurgitation Trial will provide long-awaited information on controversial therapies for this morbid disease process.